Cargando…

Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases

BACKGROUND: Cardiovascular diseases (CVD) is a major cause of death globally, and accurate risk assessment is important for identifying high-risk individuals. This study aimed to validate the laboratory-based Globorisk score for predicting CVD in the Turkish population and to develop a Turkish popul...

Descripción completa

Detalles Bibliográficos
Autores principales: Emecen, A N, Siyve, N, Unal, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595898/
http://dx.doi.org/10.1093/eurpub/ckad160.365
_version_ 1785124977195876352
author Emecen, A N
Siyve, N
Unal, B
author_facet Emecen, A N
Siyve, N
Unal, B
author_sort Emecen, A N
collection PubMed
description BACKGROUND: Cardiovascular diseases (CVD) is a major cause of death globally, and accurate risk assessment is important for identifying high-risk individuals. This study aimed to validate the laboratory-based Globorisk score for predicting CVD in the Turkish population and to develop a Turkish population-specific model. METHODS: We analyzed data from Turkey's Chronic Diseases and Risk Factors study, which examined CVD incidence from 2011 until 2017. After excluding those with prior CVD history, a total of 7239 individuals aged 40 to 80 years were included in the analysis. The performance of Globorisk in predicting CVD was assessed using the C-index. With demographic, dietary, anthropometric and Globorisk variables; we used backward stepwise logistic regression to select the final model (Turkish CVD-TCVD). Lastly, the TCVD model was internally validated and calibrated with 200 bootstrap replicates. RESULTS: Out of 7239 participants (mean age: 53.9±10.3), women: 52.3%); 766 developed CVD within six years (cumulative incidence rate: 10.6%). The C-index of the Globorisk was 0.72 with sensitivity and specificity being 68.2% and 67.3%. In the final TCVD model, backward stepwise selection identified age (odds ratio-OR: 1.06, 95% Cl: 1.05-1.07), diabetes (OR:1.83, 1.47-2.28), body mass index (OR:1.02, 1.01-1.04), high waist-hip ratio (OR:1.37, 1.13-1.66) and systolic blood pressure (OR:1.01, 1.00-1.01) as significant predictors for CVD. C-index was 0.73 with sensitivity and specificity being 72.9%, and 62.9%. Examination of the calibration plot showed signs of overprediction when the actual CVD probability was >20%. CONCLUSIONS: Laboratory-based Globorisk score had a good fit in the Turkish population. TCVD model had better sensitivity than Globorisk. Adding of waist-hip ratio to the Globorisk score could improve predictive CVD models in the Turkish population. KEY MESSAGES: • External validation of laboratory-based Globorisk showed good predictive accuracy in the Turkish population. • Although more challenging to measure, adding of waist-hip ratio to the laboratory-based Globorisk score could improve predictive cardiovascular disease models in the Turkish population.
format Online
Article
Text
id pubmed-10595898
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105958982023-10-25 Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases Emecen, A N Siyve, N Unal, B Eur J Public Health Parallel Programme BACKGROUND: Cardiovascular diseases (CVD) is a major cause of death globally, and accurate risk assessment is important for identifying high-risk individuals. This study aimed to validate the laboratory-based Globorisk score for predicting CVD in the Turkish population and to develop a Turkish population-specific model. METHODS: We analyzed data from Turkey's Chronic Diseases and Risk Factors study, which examined CVD incidence from 2011 until 2017. After excluding those with prior CVD history, a total of 7239 individuals aged 40 to 80 years were included in the analysis. The performance of Globorisk in predicting CVD was assessed using the C-index. With demographic, dietary, anthropometric and Globorisk variables; we used backward stepwise logistic regression to select the final model (Turkish CVD-TCVD). Lastly, the TCVD model was internally validated and calibrated with 200 bootstrap replicates. RESULTS: Out of 7239 participants (mean age: 53.9±10.3), women: 52.3%); 766 developed CVD within six years (cumulative incidence rate: 10.6%). The C-index of the Globorisk was 0.72 with sensitivity and specificity being 68.2% and 67.3%. In the final TCVD model, backward stepwise selection identified age (odds ratio-OR: 1.06, 95% Cl: 1.05-1.07), diabetes (OR:1.83, 1.47-2.28), body mass index (OR:1.02, 1.01-1.04), high waist-hip ratio (OR:1.37, 1.13-1.66) and systolic blood pressure (OR:1.01, 1.00-1.01) as significant predictors for CVD. C-index was 0.73 with sensitivity and specificity being 72.9%, and 62.9%. Examination of the calibration plot showed signs of overprediction when the actual CVD probability was >20%. CONCLUSIONS: Laboratory-based Globorisk score had a good fit in the Turkish population. TCVD model had better sensitivity than Globorisk. Adding of waist-hip ratio to the Globorisk score could improve predictive CVD models in the Turkish population. KEY MESSAGES: • External validation of laboratory-based Globorisk showed good predictive accuracy in the Turkish population. • Although more challenging to measure, adding of waist-hip ratio to the laboratory-based Globorisk score could improve predictive cardiovascular disease models in the Turkish population. Oxford University Press 2023-10-24 /pmc/articles/PMC10595898/ http://dx.doi.org/10.1093/eurpub/ckad160.365 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Parallel Programme
Emecen, A N
Siyve, N
Unal, B
Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases
title Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases
title_full Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases
title_fullStr Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases
title_full_unstemmed Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases
title_short Validation of Globorisk in Turkish people and development of a new model for cardiovascular diseases
title_sort validation of globorisk in turkish people and development of a new model for cardiovascular diseases
topic Parallel Programme
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595898/
http://dx.doi.org/10.1093/eurpub/ckad160.365
work_keys_str_mv AT emecenan validationofgloboriskinturkishpeopleanddevelopmentofanewmodelforcardiovasculardiseases
AT siyven validationofgloboriskinturkishpeopleanddevelopmentofanewmodelforcardiovasculardiseases
AT unalb validationofgloboriskinturkishpeopleanddevelopmentofanewmodelforcardiovasculardiseases